| Name | Title | Contact Details |
|---|
Create the most delightful experiences for our guests. We believe we can positively change the way people think about alternative lodging. The process begins by seeking out high-quality homes with modern spaces and prime locations, to ensure our designers can bring out the natural beauty of each property and to give you an authentic travel experience. We deck out each Domio with curated furniture, accessories and artwork to create a distinguished level of style and comfort, and provide round-the-clock concierge services for your convenience. With Domio, feel at home anywhere in the world.
Alive Hospice has been offering loving care to people with life-threatening illnesses, support to their families and service to the community in a spirit of enriching lives since 1975. As the oldest community-based hospice in Middle Tennessee, we
Infinata is a Norwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MicroSurgical Technology is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.